# Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.

> **NCT00291889** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 50 (actual)

## Conditions studied

- Tuberculosis (TB)

## Interventions

- **BIOLOGICAL:** Mtb72F/AS02.

## Key facts

- **NCT ID:** NCT00291889
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2005-05
- **Final completion:** 2005-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00291889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00291889, "Safety and Immunogenicity of GSK Biological's Candidate Tuberculosis Vaccine Mtb72F/AS02 in Healthy PPD-negative Adults.". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00291889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*